Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis

F. Ma, Y. Zhu, L. Chang, J. Gong, Y. Luo, J. Dai, H. Lu

. 2022 ; 71 (6) : 771-781. [pub] 20221013

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22029575

The aim of the present study was to explore whether hydrogen sulfide (H2S) protects against ischemic heart failure (HF) by inhibiting the necroptosis pathway. Mice were randomized into Sham, myocardial infarction (MI), MI + propargylglycine (PAG) and MI + sodium hydrosulfide (NaHS) group, respectively. The MI model was induced by ligating the left anterior descending coronary artery. PAG was intraperitoneally administered at a dose of 50 mg/kg/day for 4 weeks, and NaHS at a dose of 4 mg/kg/day for the same period. At 4 weeks after MI, the following were observed: A significant decrease in the cardiac function, as evidenced by a decline in ejection fraction (EF) and fractional shortening (FS); an increase in plasma myocardial injury markers, such as creatine kinase-MB (CK-MB) and cardiac troponin I (cTNI); an increase in myocardial collagen content in the heart tissues; and a decrease of H2S level in plasma and heart tissues. Furthermore, the expression levels of necroptosis-related markers such as receptor interacting protein kinase 1 (RIP1), RIP3 and mixed lineage kinase domain-like protein (MLKL) were upregulated after MI. NaHS treatment increased H2S levels in plasma and heart tissues, preserving the cardiac function by increasing EF and FS, decreasing plasma CK-MB and cTNI and reducing collagen content. Additionally, NaHS treatment significantly downregulated the RIP1/RIP3/MLKL pathway. While, PAG treatment aggravated cardiac function by activated the RIP1/RIP3/MLKL pathway. Overall, the present study concluded that H2S protected against ischemic HF by inhibiting RIP1/RIP3/MLKL-mediated necroptosis which could be a potential target treatment for ischemic HF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22029575
003      
CZ-PrNML
005      
20230519092952.0
007      
ta
008      
230113s2022 xr da f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934905 $2 doi
035    __
$a (PubMed)36281723
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ma, Fenfen $u Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai, China
245    10
$a Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis / $c F. Ma, Y. Zhu, L. Chang, J. Gong, Y. Luo, J. Dai, H. Lu
520    9_
$a The aim of the present study was to explore whether hydrogen sulfide (H2S) protects against ischemic heart failure (HF) by inhibiting the necroptosis pathway. Mice were randomized into Sham, myocardial infarction (MI), MI + propargylglycine (PAG) and MI + sodium hydrosulfide (NaHS) group, respectively. The MI model was induced by ligating the left anterior descending coronary artery. PAG was intraperitoneally administered at a dose of 50 mg/kg/day for 4 weeks, and NaHS at a dose of 4 mg/kg/day for the same period. At 4 weeks after MI, the following were observed: A significant decrease in the cardiac function, as evidenced by a decline in ejection fraction (EF) and fractional shortening (FS); an increase in plasma myocardial injury markers, such as creatine kinase-MB (CK-MB) and cardiac troponin I (cTNI); an increase in myocardial collagen content in the heart tissues; and a decrease of H2S level in plasma and heart tissues. Furthermore, the expression levels of necroptosis-related markers such as receptor interacting protein kinase 1 (RIP1), RIP3 and mixed lineage kinase domain-like protein (MLKL) were upregulated after MI. NaHS treatment increased H2S levels in plasma and heart tissues, preserving the cardiac function by increasing EF and FS, decreasing plasma CK-MB and cTNI and reducing collagen content. Additionally, NaHS treatment significantly downregulated the RIP1/RIP3/MLKL pathway. While, PAG treatment aggravated cardiac function by activated the RIP1/RIP3/MLKL pathway. Overall, the present study concluded that H2S protected against ischemic HF by inhibiting RIP1/RIP3/MLKL-mediated necroptosis which could be a potential target treatment for ischemic HF.
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    12
$a sulfan $7 D006862
650    _2
$a nekroptóza $7 D000079302
650    _2
$a proteinkinasy $x metabolismus $7 D011494
650    12
$a infarkt myokardu $x prevence a kontrola $7 D009203
650    12
$a srdeční selhání $x farmakoterapie $x prevence a kontrola $7 D006333
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zhu, Yahong $u Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai, China
700    1_
$a Chang, Lingling $u School of Pharmacy, Fudan University, Shanghai, China
700    1_
$a Gong, Jingru $u Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai, China
700    1_
$a Luo, Ying $u Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai, China
700    1_
$a Dai, Jing $u Department of Clinical Diagnostics, Hebei Medical University, Shijiazhuang, Hebei, China
700    1_
$a Lu, Huiping $u Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai, China
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 71, č. 6 (2022), s. 771-781
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36281723 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20230113 $b ABA008
991    __
$a 20230519092945 $b ABA008
999    __
$a ok $b bmc $g 1894770 $s 1180900
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 71 $c 6 $d 771-781 $e 20221013 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK198 $a Pubmed-20230113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace